Purpose: Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, increases rhabdosphincter contractility via the stimulation of pudendal motor neuron ␣-1 adrenergic and 5-hydroxytryptamine-2 receptors. In this first phase 3 study we assessed the efficacy and safety of duloxetine in women with stress urinary incontinence (SUI).
Stress urinary incontinence (SUI) is the complaint of involuntary leakage of urine during effort, exertion, sneezing or coughing. 1 It is the most common type of urinary incontinence in women with 78% of women presenting with the symptom of SUI in a pure (49%) or mixed (29%) form. 2 In the United States it is estimated that 29.5 million have SUI in a pure or mixed form. Treatment for SUI is limited to pelvic floor muscle training, various types of devices, behavioral interventions and surgery. There is no globally approved pharmaceutical treatment.
Animal studies have implicated serotonin and norepinephrine in the neural control of lower urinary tract function. In cats serotonergic agonists suppress parasympathetic activity and enhance sympathetic and somatic activity, 3, 4 effects that promote urine storage by relaxing the bladder and increasing outlet resistance. Norepinephrine variably affects the lower urinary tract depending on the adrenergic receptor subtype with which it interacts. 5Ϫ8 Duloxetine, which is a balanced and potent inhibitor of serotonin and norepinephrine reuptake, has been demonstrated to increase bladder capacity and striated urethral sphincter activity through central actions in the spinal cord in the cat. 9 These storage promoting effects are unique to dual reuptake inhibition in a single molecule and they were not duplicated by the administration of 2 single reuptake inhibitors. 10 The ability of duloxetine to stimulate pudendal motor neurons and increase striated urethral sphincter contractility is thought to be the basis for its efficacy in women with SUI, as demonstrated in a recent phase 2 trial. 11 We report the results of the first completed phase 3 trial of 40 mg duloxetine twice daily, which was the optimum dose in the phase 2 trial, in women with SUI.
MATERIALS AND METHODS
Nonpregnant women 18 years and older with a clinical diagnosis of bothersome SUI at least 3 months in duration participated in this double-blind, placebo controlled, randomized clinical trial at 55 study centers in Canada and the United States. Written informed consent was obtained from all participants. To enroll subjects must have reported a predominant symptom of SUI with 7 or greater stress incontinent episodes weekly. Additional history requirements included daytime voiding frequency less than 8 times daily, nocturnal frequency less than 3 times daily and no predominant urge incontinence symptoms. Subjects unable to tolerate retrograde bladder filling to 400 ml or who had a first sensation of bladder filling at less than 100 ml were excluded. After filling a positive cough stress test and stress pad test were required. This clinical algorithm has been demonstrated to predict urodynamic stress incontinence with 92% accuracy.
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After screening, a 2-week, no drug lead-in period and a 2-week, placebo lead-in period subjects were randomized under double-blind conditions to 12 weeks of 80 mg duloxetine daily or placebo given as 2 identical capsules twice daily. Subjects were seen at 4-week intervals. A centralized computer voice response system controlled randomization. Stratified randomization using baseline incontinence episode frequency (IEF) of less than 14 or 14 or greater episodes weekly was used to prevent potential imbalance in incontinence severity. Treatment assignments were also balanced at each investigative site.
One of the 2 primary efficacy variables was IEF, which was calculated from subject completed real-time paper diaries that were also used to record voids. Two 7-day diaries were completed before randomization, that is 1 during 2 week of the no drug lead-in period and 1 during week 2 of the blinded placebo lead-in period. Three diaries were completed during active treatment, that is 1 week before each visit.
The second primary efficacy variable was the Incontinence Quality of Life (I-QOL) questionnaire total score. 12 This validated disease specific instrument, which was administered at each visit, evaluates the effects of urinary incontinence in the 3 domains of avoidance and limiting behavior, social embarrassment and psychosocial impact, and it is endorsed by the International Consultation on Incontinence. 13 A score of 100 represents the best possible quality of life and 0 represents the worst possible quality of life.
Another validated measure, namely the Patient Global Impression of Improvement (PGI-I) rating, was obtained at each post-randomization visit. This single question measures subject self-perceived improvement in the condition since starting treatment.
14 A Patient Global Impression of Severity 14 rating was completed only at baseline. In addition, subjects completed the Beck Depression Inventory-II (BDI-II) 15 at the randomization and last treatment visits. Subjects on antidepressants were excluded from the trial.
Safety was assessed by the evaluation of treatment emergent adverse events, discontinuation for adverse events, vital signs and laboratory tests. Adverse events were elicited by nonprobing inquiry at each visit and recorded regardless of perceived causality. An event was considered treatment emergent if it occurred for the first time or worsened during the double-blind treatment period.
The statistical analysis plan was specified a priori. The percent change in IEF was compared between treatment groups using van Elteren's test, a type of stratified Wilcoxon test, with baseline incontinence severity as the stratification variable. The percent change in IEF is reported as a median because extreme outliers (placebo 700% and duloxetine 550%) substantially distorted the mean. Primary analysis used the last visit diary for baseline and treatment phases. Mean changes in I-QOL scores were analyzed using an ANCOVA model that included terms for baseline scores, treatment, site and baseline incontinence severity. The same ANCOVA model was used to analyze voiding intervals. Categorical variables were analyzed using Pearson's chi-square or Fisher's exact test. Sample size provided approximately 90% power to detect a treatment difference of 20% in the median percent change in IEF and 3.5 points in the mean change in I-QOL total score at a 0.05 type I error level. All primary analyses used the intent-to-treat (ITT) principle using data on each randomized subject with at least 1 post-randomization measure. Because subjects who discontinued the trial prematurely may have experienced benefits that could have biased results, efficacy was also evaluated in subjects who completed the trial. For prematurely discontinuing subjects the last outcome measure was carried forward only in ITT analysis. No data were collected after discontinuation. Analyses were performed using SAS 8.1 (SAS Institute, Cary, North Carolina) with 2-sided ␣ ϭ 0.05 considered significant.
RESULTS
A total of 683 women 22 to 84 years old were randomized to duloxetine (344) or placebo (339) between November 2000 and November 2001. Of the participants 89% (83% on duloxetine and 95% on placebo) completed at least 1 postrandomization diary and 97% (97% on duloxetine and 98% on placebo) completed an I-QOL questionnaire and were included in ITT analysis. Of placebo treated subjects 87% completed the study compared with 69% of duloxetine treated subjects (p Ͻ0.001). The difference was primarily attributable to a higher rate of duloxetine early discontinuation related to side effects. Placebo treated subjects ingested an average of 93% of doses compared with 80% in the duloxetine group (p Ͻ0.001). This compliance difference was attributable to limited duloxetine consumption by subjects who discontinued early and it was not significant after the first post-randomization visit. Table 1 lists baseline demographic and incontinence data that indicated no significant differences between the treatment groups. Approximately two-thirds of subjects considered urinary tract function to be moderately or severely abnormal and had an average of 2 or more daily incontinence episodes. Mean BDI-II scores were well below the cutoff level of 17 or greater associated with appreciable symptoms of depression.
The decrease in IEF was significantly greater in the duloxetine group on ITT and study completion analysis (table  1) . On ITT analysis the duloxetine treated group had a median absolute decrease in IEF of 7 per week compared with 3 per week in the placebo treated group (p Ͻ0.001). The significant duloxetine treatment response was unaffected by baseline incontinence severity.
On ITT analysis 51.4% of participants in the duloxetine group had a 50% to 100% decrease in IEF compared with 33.5% in those in the placebo group (p Ͻ0.001). At the last diary 10.5% of subjects in the duloxetine group had no incontinence episodes compared with 5.9% in the placebo group (p Ͻ0.05). Superior IEF improvements with duloxetine were observed at the first post-randomization visit at 4 weeks and they persisted throughout the 12-week double-blind treatment period ( fig. 1 ). In the duloxetine group the average
Duloxetine subjects showed significant improvements in I-QOL scores compared with placebo subjects (table 2) . These improvements were also apparent by the first postrandomization visit and they were maintained throughout the trial (fig. 2) . Similar significant improvements were observed in all I-QOL subscales (table 2) . On the PGI-I 62.0% of duloxetine treated subjects rated the condition as improved compared with 39.6% of placebo treated subjects (p Ͻ0.001).
Mean BDI-II scores, which were normal at baseline and after treatment, did not change significantly with duloxetine or placebo. Only 23 subjects (15 on duloxetine) had appreciable symptoms of depression (BDI-II 17 or greater). This group did not show significant improvement in the total I-QOL score on duloxetine compared with placebo, although the small number of subjects limited the power of this finding.
Treatment emergent adverse events were experienced by more subjects in the duloxetine group (74% vs 50%, p Ͻ0.001). Table 3 lists all side effects that were significantly more common with duloxetine and occurred in at least 5% of subjects on duloxetine. Nausea was the most common side effect, with duloxetine, with 91% of cases reported within 4 weeks of starting therapy, most within the first 2 days. Nausea was mild to moderate in severity in 87% of the subjects, increasing in only 1 of 68. Of the subjects in whom nausea developed while on duloxetine, 74% completed the study, including 53% and 81% who reported nausea resolution by 1 week and within 1 month, respectively.
The adverse event discontinuation rate was significantly higher in the duloxetine group (24.1% vs 4.1%, p Ͻ0.001). Table 3 lists all adverse events with a discontinuation rate of greater than 1% for duloxetine. Of adverse event discontinuations 89% occurred within the first 4 weeks of treatment. None of the 31 subjects on duloxetine who experienced dry mouth and 1 of the 30 (3%) who experienced constipation discontinued due to these adverse events. Serious adverse events, cardiovascular events and laboratory abnormalities were rare and not significantly more common in the duloxetine group.
DISCUSSION
While many women have relatively minor degrees of SUI and may believe that the condition does not warrant treatment, SUI is bothersome and severe in 17% to 24% of women with incontinence. 16 Thus, between 3 and 7 million American women have severe or bothersome SUI in a pure or mixed form. In 1997 fewer than 130,000 women (less than 5%) underwent continence surgery in the United States. 17 This limited use of surgery may be related to a number of factors, such as concern over expense, complications, risks, time lost from work or other activities, or to the intermittent nature of the problem.
An undetermined number of women with SUI use various forms of pelvic floor muscle training (PFMT), although they often fail to comply with a PFMT program acutely and chronically. In a study 61% of women for whom PFMT was prescribed for SUI trained only once weekly (15%), once monthly (3%) or not at all (43%). 18 It is possible that some women are discouraged by the relatively slow response with PFMT and, thus, they fail to comply with recommended trial schedules.
Duloxetine has a predominant central mode of action through the sacral cord pudendal motor nucleus to stimulate the urethral rhabdosphincter rather than a peripheral mode of action to stimulate smooth muscle of the urethra, 9 which is the presumed mode of action of various direct (for example phenylpropanolamine and ephedrine) and indirect (for example imipramine) peripheral ␣-adrenergic agents. Thus, the cardiovascular and cerebrovascular risks inherent with the off label use of these agonists 19, 20 should be avoided with duloxetine. In the current study duloxetine was not associated with any change in blood pressure or clinically worrisome changes on electrocardiogram.
Using several measures of efficacy duloxetine was significantly more effective than placebo in women with SUI. On ITT and study completion analyses a 50% to 100% decrease in incontinence episodes was seen in more than half of the women treated with duloxetine, while 10.5% experienced no incontinence episodes. These effects were noted early in treatment, persisted for the duration of the 3-month study and were independent of initial incontinence severity. The IEF response while on duloxetine was observed although the average voiding interval increased 20 minutes, indicating that incontinence improvement did not result from more frequent bladder emptying as a behavior learned during the trial.
Quality of life measure improvements were also apparent within the first 4 weeks of treatment and they persisted throughout the trial. Significant improvement in all I-QOL subscales allows some characterization of the type of improvements experienced while on duloxetine. Psychosocial impact subscale improvements reflect increased ability to leave home or perform activities previously restricted by leakage and an ability to enjoy life more, feel less helpless and worry less about wearing certain types of clothing or participating in sexual activity. Avoidance and limiting behavior subscale improvements reflect increased independence of the need to plan every activity around the availability of a toilet, and ability to perform physical activities and avoid fluid restrictions. Social embarrassment subscale improvements reflect less worry over odor or embarrassment, or the possibility that incontinence may worsen with time.
The small percent of subjects with appreciable symptoms of depression and their insignificant changes in I-QOL scores demonstrate that an improvement in unrecognized depression as a consequence of the known antidepressant effect of duloxetine was not an important factor in the overall quality of life improvements while on duloxetine. The lack of a significant change in mean BDI-II scores in this study indicates that duloxetine did not exert significant effects on mood in nondepressed women, who made up 96% of the duloxetine group.
The PGI-I global improvement scale helps put the IEF and I-QOL improvements into clinical perspective. We have previously reported that women with SUI who rate themselves improved using the PGI-I scale have a decrease in IEF of 43.4% or greater and improvements in I-QOL scores of 6.4 points or more.
14 In contrast to placebo, the duloxetine associated median decrease in IEF (50%) and mean improvement in I-QOL (11.1 points) were well above these threshold values.
Significantly more patients experienced treatment emergent adverse events due to duloxetine than to placebo and 24% of subjects on duloxetine discontinued therapy due to side effects. Nausea was the most frequent side effect with 6.4% of all subjects on duloxetine discontinuing due to nausea. Nausea tended to start early after initiating duloxetine and in most cases it was mild or moderate, did not worsen and resolved within 1 week to 1 month. Of the women who experienced treatment emergent nausea 74% completed the study. Dry mouth and constipation were not uncommon but together they resulted in a single discontinuation.
Clearly improvements due to duloxetine must be weighed against a considerable discontinuation rate due to early side effects. It remains to be established whether more patients would continue duloxetine in clinical practice if they are reassured that any early side effects are unlikely to worsen or persist based on clinical trial experience. However, the data suggest that within 4 weeks a patient with incontinence and her physician should be able to assess the adequacy of the response to duloxetine by comparing improvement with any residual side effects. In conclusion, these efficacy and safety data support duloxetine as potentially the first approved pharmacological treatment for women with bothersome SUI, expanding the treatment options available to these women. Mean improvement in I-QOL total score for duloxetine and placebo at each of 3 visits during randomized, double-blind 12-week trial. Separation of duloxetine response from placebo response was significant at each visit and onset of effect was evident at postrandomization visit 1. 
